10-K: Network-1 2025 10-K: Patent Monetization & Biotech Focus

Network-1 Technologies reports a net loss for 2025, driven by operating expenses and equity investment losses, while continuing its patent monetization strategy and biotech investment.

Summary

• The principal business is the development, licensing, and protection of intellectual property assets, owning 119 U.S. patents (54 expired) and 15 foreign patents.
• Key patent portfolios include M2M/IoT, HFT, Cox, and Smart Home, with Remote Power and Mirror Worlds patents having expired and no longer being monetized.
• An investment of $7,000,000 has been made in ILiAD Biotechnologies, Inc., a clinical-stage biotechnology company, representing approximately 6.4% ownership on a non-fully diluted basis as of December 31, 2025.
• Revenue for the year ended December 31, 2025, was $150,000, entirely derived from a litigation settlement involving the expired Remote Power Patent.
• The company reported a net loss of $2,420,000, or $0.11 per share basic and diluted, for 2025, an improvement from a $3,034,000 net loss in 2024.
• Operating loss for 2025 was $3,306,000, a decrease from $3,621,000 in 2024, primarily due to decreased professional fees and general and administrative expenses.
• Cash and cash equivalents and marketable securities totaled $36,869,000, with working capital of $36,336,000 as of December 31, 2025.
• Ongoing patent litigations involve the M2M/IoT Patent Portfolio (against Samsung) and HFT Patent Portfolio (against Citadel, Jump Trading, and Optiver), with trial dates scheduled for June 7, 2027.
• An appeal is pending to the U.S. Court of Appeals for the Federal Circuit following a District Court's dismissal of litigation involving the Cox Patent Portfolio against Google and YouTube.
• The Board of Directors authorized an extension and increase of the share repurchase program to repurchase up to $5,000,000 of common stock over the subsequent 24-month period.
• The company repurchased 212,262 shares of common stock for $286,617 in 2025, at an average price of $1.35 per share.
• A semi-annual cash dividend of $0.05 per share ($0.10 annually) has been consistently paid and is anticipated to continue, subject to Board review.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for Network-1, marked by minimal revenue from its core IP business and continued losses, despite a strong cash position and strategic investments. The reliance on litigation for future revenue and the dilution of its biotech investment present significant uncertainties.

Positives

• Net loss decreased by $614,000 in 2025 compared to 2024, indicating an improvement in financial performance.
• Operating loss decreased by $315,000 in 2025 compared to 2024, reflecting reduced operating expenses.
• Maintains a strong liquidity position with $36,869,000 in cash and cash equivalents and marketable securities, and $36,336,000 in working capital as of December 31, 2025.
• Management believes there is sufficient cash to fund operations for the foreseeable future.
• The investment in ILiAD Biotechnologies saw a significant $115,000,000 preferred stock financing completed in February 2026, potentially validating the investment's long-term prospects.
• The share repurchase program was extended and increased to $5,000,000, demonstrating a commitment to returning capital to shareholders.
• The company continues its policy of paying semi-annual cash dividends of $0.05 per share.
• Acquired a new Smart Home Patent Portfolio in March 2025, expanding intellectual property assets.
• The court denied Citadel's motion to dismiss the HFT patent litigation, allowing the case to proceed.

Negatives

• Revenue for 2025 was only $150,000, entirely from a settlement related to an expired patent (Remote Power Patent), indicating a lack of significant monetization from active patent portfolios.
• The company reported a substantial net loss of $2,420,000 in 2025.
• The investment in ILiAD Biotechnologies resulted in a recognized net loss of $1,603,000 for 2025 and a significant dilution of ownership to 3.1% (non-fully diluted) after the February 2026 financing.
• The Cox Patent Portfolio litigation against Google and YouTube was dismissed by a District Court, requiring an appeal, indicating an unfavorable legal outcome to date for a key portfolio.
• Future revenue is highly uncertain and dependent on unpredictable litigation outcomes and the ability to monetize other patent assets.
• The company is highly dependent on the personal efforts of its CEO and Chairman, Corey M. Horowitz, and the loss of his services would have a material adverse effect.
• There is a risk of being classified as a Personal Holding Company in the future, which could result in an additional 20% tax on undistributed income.
• The dividend policy is subject to periodic review and may not be continued in the future.
• The company faces intense competition in the patent acquisition and monetization market from entities with significantly greater financial and human resources.
• Markets covered by intellectual property are subject to rapid technological change and potential technology obsolescence, which could render patents less marketable or unenforceable.
• The increasing development of artificial intelligence could negatively impact the business by enabling design-arounds, creating alternative technologies, or providing sophisticated insights to potential infringers.

Risks

• Revenue is uncertain as it is dependent upon litigation outcomes involving patents, which are unpredictable.
• Inability to protect patents would negatively impact the business, including unfavorable outcomes in litigation or USPTO post-grant inter partes review proceedings (IPRs).
• May not achieve successful outcomes of litigations involving the HFT Patent Portfolio or M2M/IoT Patent Portfolio, which would materially impact future revenue and net income.
• The outcome of the substantial $7,000,000 investment in ILiAD Biotechnologies is uncertain and subject to substantial risks.
• Past dependence on the Remote Power Patent for a significant portion of revenue; future revenue is dependent on the ability to monetize other patents.
• May not be able to capitalize on the strategy to acquire high-quality patents with significant licensing opportunities or enter into strategic relationships with third parties.
• The patent monetization cycle is long, costly, and unpredictable, with significant time lags between acquisition and revenue recognition.
• Quarterly and annual operating and financial results are difficult to predict and are likely to fluctuate significantly.
• Could be classified as a Personal Holding Company in the future, resulting in a 20% tax on undistributed personal holding company income.
• The company is dependent upon its CEO and Chairman, Corey M. Horowitz; the loss of his services would have a material adverse effect.
• Cash dividends may not be continued to be paid, as the dividend policy is subject to change.
• Legislation, regulations, court rulings, and actions by the USPTO have materially increased the risk and cost of patent enforcement and may continue to do so.
• The increasing development of artificial intelligence could impact the business by enabling design-arounds, creating alternative technologies, or empowering potential infringers with sophisticated insights.
• Changes in patent law could adversely impact the business by altering protections or making enforcement more difficult.
• Pending patent infringement litigations are time-consuming and costly, potentially affecting other business opportunities.
• Faces intense competition to acquire intellectual property and enter into strategic relationships from companies with significantly greater resources.
• Markets are subject to rapid technological change, and technologies face potential obsolescence due to new products, industry standards, or competing technologies.
• The burdens of being a public company may adversely affect the ability to pursue litigation due to time, attention, financial resources, and disclosure obligations.
• Investors may have limited influence on stockholder decisions because ownership of common stock is concentrated (executive officers and directors beneficially owned 32.6% as of February 15, 2026).
• Common stock may be delisted from the NYSE American exchange if the company fails to comply with continued listing standards.
• Inherent uncertainties involved in estimates, judgments, and assumptions used in financial statements could have a material adverse effect on business, financial condition, and operating results.
• Provisions in the corporate charter, by-laws, and Delaware law could make it more difficult for a third party to acquire the company, discouraging takeovers.
• The stock price may be highly volatile and could fluctuate widely in response to various factors, including litigation outcomes, investment in ILiAD, ability to acquire IP, technology changes, AI development, regulatory changes, and economic factors.

Future Outlook

The company anticipates continuing its licensing efforts and monetization of its patent portfolios, including M2M/IoT, HFT, Cox (contingent on appeal success), and Smart Home. It plans to seek additional high-quality intellectual property assets and evaluate other strategic opportunities. Management believes the current cash position is sufficient to fund operations for the foreseeable future. Future operating results are expected to fluctuate significantly due to the timing and success of patent litigation and the return on its ILiAD investment.

Management Comments

• "Our current strategy includes continuing our efforts to monetize our intellectual property."
• "We continue to seek to acquire additional intellectual property assets to develop, commercialize, license or otherwise monetize."
• "Based on our current cash position, we believe that we will have sufficient cash to fund our operations for the foreseeable future."
• "At this time, we anticipate continuing to pay dividends consistent with our policy."
• "The Company and Mr. Horowitz are in discussions to extend his employment agreement."

Industry Context

StockSavvy.ai notes that Network-1 operates in the highly specialized and competitive intellectual property licensing and enforcement industry, facing established players like Acacia Research Corporation, Intellectual Ventures, WI-LAN Inc., and RPX Corporation, as well as litigation funding firms. The industry is characterized by significant legal risks, high costs, and unpredictable revenue streams tied to litigation outcomes. The increasing development of AI poses a new challenge, potentially enabling design-arounds or strengthening infringers' legal positions, which could further complicate patent monetization efforts. The investment in ILiAD Biotechnologies represents a diversification into the clinical-stage biotechnology sector, a high-risk, high-reward area distinct from its core IP business.

Comparison to Industry Standards

• Network-1's revenue of $150,000 in 2025, derived solely from an expired patent, is significantly lower than major IP monetization firms. For example, Acacia Research Corporation (NASDAQ:ACTG) reported revenues in the tens to hundreds of millions in recent years, indicating Network-1 operates on a much smaller scale or is in a trough period between major licensing events.
• The company's net loss of $2.42 million, while an improvement, highlights the inherent volatility and cost structure of a business heavily reliant on patent litigation, where legal expenses and the timing of settlements can lead to inconsistent profitability.
• The investment in ILiAD Biotechnologies, a clinical-stage company, aligns with a venture capital model rather than typical IP firm investments, comparable to early-stage biotech investments by specialized funds like RA Capital Management (which led ILiAD's recent financing), rather than direct comparisons to other IP firms.
• The share repurchase program and consistent dividend policy, despite losses, suggest a management focus on returning capital to shareholders, which is common among mature companies with strong cash reserves but less typical for companies with highly volatile revenue streams and significant R&D-like (litigation) expenses.

Management Changes

Corporate Governance

Legal Proceedings

• **M2M/IoT Patent Portfolio Litigation**: Commenced litigation against Samsung Electronics Co., LTD and Samsung Electronics America, Inc. on June 27, 2025, in the U.S. District Court for the Eastern District of Texas for infringement of six patents related to eSIM and 5G technologies. A trial date is scheduled for June 7, 2027.
• **HFT Patent Portfolio Litigation**: Initiated litigations against Citadel Securities, LLC and Jump Trading, LLC on December 24, 2024, in the U.S. District Court for the Northern District of Illinois for infringement of three patents. Citadel's motion to dismiss was denied on December 1, 2025, and it filed its answer and counterclaims on January 5, 2026. Jump Trading filed an answer and counterclaims on April 7, 2025. Additionally, litigation was commenced against Optiver US LLC and Optiver Trading US LLC on September 8, 2025, in the U.S. District Court for the Western District of Texas for infringement of the same three patents, with a trial date scheduled for June 7, 2027.
• **Cox Patent Portfolio Litigation**: Initiated litigation against Google Inc. and YouTube, LLC in April and December 2014. The U.S. District Court dismissed the patent infringement claims in April 2024, finding two patents invalid and one not infringed. A notice of appeal was filed on May 14, 2024, to the U.S. Court of Appeals for the Federal Circuit, and oral argument took place on March 9, 2026, with a decision pending.
• **Remote Power Patent Litigation**: Received an additional settlement payment of $150,000 on February 21, 2025, from a defendant in litigation involving the now-expired Remote Power Patent.

Related Party Transactions

• John Nix, Managing Member of M2M (from whom the M2M/IoT Patent Portfolio was acquired), provides consulting services to the company.
• Dr. Ingemar Cox (from whom the Cox Patent Portfolio was acquired) provides consulting services to the company.
• Corey M. Horowitz, Chairman and Chief Executive Officer, receives incentive compensation based on a percentage of royalties or other payments from licensing activities related to the company's patents and investment in ILiAD.
• The company and Corey M. Horowitz are in discussions to extend his employment agreement.
• Jonathan E. Greene, Executive Vice President, serves as a member of the Strategic Development Committee.
• Executive officers and directors, as a group, beneficially owned 32.6% of the outstanding common stock as of February 15, 2026, indicating concentrated ownership.

Stakeholder Impact

• **Shareholders**: Face potential for future dividends and benefits from the share repurchase program, but also significant risks from uncertain litigation outcomes, potential for continued losses, and stock price volatility. Concentrated ownership by insiders may limit the influence of other stockholders.
• **Employees and Consultants**: The company employs two full-time employees and two consultants, whose compensation includes salary, bonuses, and restricted stock units. Their continued employment and compensation are tied to the company's financial performance and strategic direction.
• **Customers/Licensees**: Companies potentially infringing the company's patents face litigation, while existing licensees operate under established agreements. The company's strategy is to expand its licensing base.
• **ILiAD Biotechnologies**: Network-1 is a significant investor, providing capital and strategic support, but its ownership has been diluted following ILiAD's recent financing. The success of ILiAD's BPZE1 vaccine development directly impacts the value of Network-1's investment.
• **Creditors**: The company's strong cash and working capital position provides a buffer, but ongoing losses and uncertain future revenue streams could impact long-term creditworthiness if not addressed by successful patent monetization.

Next Steps

• Continue efforts to monetize the M2M/IoT, HFT, and Smart Home patent portfolios.
• Pursue the appeal in the Cox Patent Portfolio litigation against Google and YouTube.
• Seek to acquire additional high-quality intellectual property assets.
• Evaluate other strategic alternatives for business development.
• Engage in discussions to extend CEO Corey M. Horowitz's employment agreement.
• Continue share repurchases under the extended $5,000,000 program.
• Continue semi-annual cash dividends, subject to periodic review by the Board of Directors.
• Prepare for scheduled trials on June 7, 2027, for the Samsung (M2M/IoT) and Optiver (HFT) litigations.

Key Dates

Recommendation

The company faces significant challenges with minimal revenue from its core IP business and ongoing net losses, making it a speculative investment. However, its substantial cash reserves, active pursuit of new patent monetization opportunities, and continued dividend payments and share repurchases provide some stability and potential for future upside if litigation outcomes are favorable or the ILiAD investment proves successful. The high-risk, high-reward nature of patent litigation and biotech investment warrants a cautious "hold" for investors already in, while new investors might wait for clearer signs of successful monetization.

Keywords

Intellectual Property, Patent Licensing, SEC Filing, 10-K, Biotechnology Investment, M2M/IoT, High Frequency Trading, Smart Home Technology, Patent Litigation, Corporate Governance, Share Repurchase, Dividends, eSIM, Whooping Cough Vaccine